Document:

Form of Non-Qualified Stock Option Agreement

 Exhibit 10.13 
 MEMSIC, INC. 
 NON-QUALIFIED STOCK OPTION AGREEMENT 
 NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) by and between MEMSIC, Inc., a Delaware corporation (the “Company”),
and the director, officer, employee, or consultant of the Company (the “Optionee”) specified on Schedule A appended to this Agreement (“Schedule A”). 
 WHEREAS, the Company maintains the MEMSIC, Inc. 2007 Stock Incentive Plan (the “Plan”); and 
 WHEREAS, the Optionee renders important services to the Company, and the Company desires to grant a stock option to the Optionee; and 
 WHEREAS, the Board of Directors of the Company (the “Board”) or the Compensation Committee of the Board (the “Committee”), acting pursuant to the Plan, has authorized the grant of this
Non-Qualified Stock Option to the Optionee subject to the terms and conditions of the Plan and the additional terms and conditions of this Agreement; 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Company and the Optionee hereby agree as follows: 
 1. Grant of Option. The Company hereby grants to the Optionee, and the Optionee hereby accepts, a Non-Qualified Stock Option (the
“Option”) to purchase from the Company that number of shares of the Company’s Common Stock, $0.00001 par value per share (the “Shares”), specified on Schedule A. This Agreement and the Option hereby granted to the Optionee
are subject to all of the terms and conditions of the Plan which are incorporated herein by this reference; any term used herein shall have the meaning assigned thereto in the Plan, unless such term is otherwise specifically defined herein.

 2. Option Price, Date of Grant. This Option may be exercised at the option price per Share specified in Schedule A, which the Board
or Committee has determined, in accordance with Section 6 of the Plan, is 100% of the fair market value of a Share on the Date of Grant of this Option. The Date of Grant of this Option is specified on Schedule A. 
 3. Term of Option; Vesting and Employment Requirements. This Option shall expire on the date specified on Schedule A (the “Expiration
Date”). This Option shall be exercisable to the extent of the number of Shares vested as of the date of exercise, in accordance with the vesting schedule provided on Schedule A. If exercised in part, the Option may be exercised only once in
each calendar quarter, except with the express written consent of the Company. The vesting installments provided in Schedule A are cumulative, and this Option will remain exercisable with respect to all vested but unexercised installments until the
Option expires on the Expiration Date, unless the Option is sooner terminated as provided in Section 7 or Section 8 of this Agreement. 

 4. Other Conditions and Limitations. The Option shall not be assignable or transferable by the
Optionee otherwise than by will or by the laws of descent and distribution, and the Option shall be exercisable during the lifetime of the Optionee by the Optionee only. 
 5. Exercise of Option. Written notice of the exercise of the Option or any portion thereof shall be given to the Chief Financial Officer of the Company accompanied by the option price (i) in cash or by
check, (ii) if permitted by the Board or Committee, by delivery and assignment to the Company of Shares having a value equal to the option price, (iii) if permitted by the Board or Committee, by delivery of the Optionee’s personal
recourse note, or (iv) if permitted by the Board or Committee, a combination of (i), (ii) and (iii). 
 6. Stock Dividends;
Stock Splits; Stock Combinations; Recapitalizations. Appropriate adjustment shall be made in the maximum number of Shares subject to this Option and in the number, kind and option price of Shares covered by this Option to the extent it remains
outstanding, to give effect to any stock dividends, stock splits, stock combinations, recapitalizations and other similar changes in the capital structure of the Company after the Date of Grant of this Option, as determined by the Board or Committee
in accordance with Section 13 of the Plan. 
 7. Capital Changes and Business Successions. Upon the occurrence of any of the
following events, the Optionee’s rights with respect to this Option shall be adjusted as hereinafter provided: 
 (a) Consolidations
or Mergers. If the Company is to be consolidated with or acquired by another entity in a merger, sale of all or substantially all of the Company’s assets or otherwise (an “Acquisition”), the Board or the Committee or the board of
directors of any entity assuming the obligations of the Company hereunder, shall, as to this Option, either (i) make appropriate provision for the continuation of this Option by substituting on an equitable basis for the Shares then subject to
this Option the consideration payable with respect to the outstanding shares of Common Stock in connection with the Acquisition; or (ii) upon written notice to the Optionee, provide that this Option must be exercised, to the extent exercisable
as of the closing of the Acquisition, within a specified number of days of the date of such notice, at the end of which period this Option shall terminate; or (iii) terminate this Option in exchange for a cash payment equal to the excess of the
fair market value of the Shares subject to this Option (to the extent exercisable as of the closing of the Acquisition) over the exercise price thereof. 
 (b) Recapitalization or Reorganization. In the event of a recapitalization or reorganization of the Company (other than a transaction described in subparagraph A above) pursuant to which securities of the
Company or of another corporation are issued with respect to the outstanding shares of Common Stock, the Optionee upon exercising this Option shall be entitled to receive for the purchase price paid upon such exercise the securities he would have
received if he had exercised this Option prior to such recapitalization or reorganization. 
  

 - 2 - 

 (c) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the
Company, this Option will terminate immediately prior to the consummation of such proposed action or at such other time and subject to such other conditions as shall be determined by the Board or the Committee. 
 (d) Issuances of Securities. Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities
convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares subject to this Option. No adjustments shall be made for dividends paid in cash or in
property other than securities of the Company. 
 8. Termination of Option. In the event that the Optionee ceases for any reason to
serve as a director, officer, employee or consultant of the Company, or a subsidiary of the Company, at a time prior to the exercise of this Option in full (the date on which the Optionee so ceases to serve as a director, officer, employee or
consultant of the Company being herein referred to as the “Termination Date”), this Option may be exercised, to the extent exercisable on the Termination Date, at any time within the 180-day period following the Termination Date, after
which period this Option shall terminate and may no longer be exercised; provided, however, that (i) if the Optionee’s service as a director, officer, employee or consultant of the Company, or a subsidiary of the Company, shall have
terminated by resignation or other voluntary action by the Optionee, or if such service shall have been terminated for cause, this Option shall terminate and may no longer be exercised as of the Termination Date, and (ii) this Option may not be
exercised to any extent by anyone after the Expiration Date. For purposes of this Agreement, “cause” shall mean conviction of a crime involving moral turpitude, or any other act or omission by the Optionee which, in the reasonable, good
faith opinion of the Company, constitutes conduct which is detrimental to the best interests of the Company or a subsidiary of the Company. 
 9. [Intentionally Omitted]. 
 10. Compliance With Securities Laws. The Company shall not be obligated to sell or
issue any Shares pursuant to this Option unless the Shares with respect to which this Option is being exercised are at that time effectively registered or exempt from registration under the Securities Act of 1933, as amended (the “Act”),
and any applicable state securities or “blue sky” law (“Blue Sky Law”). In the event Shares or other securities shall be issued which shall not be so registered, the Optionee hereby represents, warrants and agrees that he will
receive such Shares or other securities for investment and not with a view to the resale or distribution thereof, and will not transfer such Shares or other securities unless they are effectively registered for such transfer under the Act and any
applicable Blue Sky Law or unless an opinion of counsel satisfactory to the Company has been received by the Company to the effect that such registration is not required. The Optionee further agrees that the stock certificate or certificates
evidencing such Shares may bear a legend setting forth such restrictions on their transferability. 
 11. Rights as a Stockholder; No
Obligation to Continue Employment. The Optionee shall have no rights as a stockholder with respect to the Shares subject to the Option until the exercise of the Option and the issuance of a stock certificate for the Shares with respect to which
the Option shall have been exercised. Nothing herein contained shall impose any 
  

 - 3 - 

 obligation on the Company or any of its subsidiaries or the Optionee with respect to continued employment or engagement
of the Optionee by the Company or any of its subsidiaries. Nothing herein contained shall impose any obligation upon the Optionee to exercise the Option. 
 12. Relationship to Plan. The Option contained in this Agreement has been granted pursuant to the Plan, and is in all respects subject to the terms, conditions and definitions of the Plan, as amended from time
to time. The Optionee hereby accepts this Option subject to all the terms and provisions of the Plan and agrees that all decisions under and interpretations of the Plan by the Board or Committee shall be final, binding and conclusive upon the
Optionee and his permitted heirs, executors, administrators, successors and assigns. 
 13. Restrictions on Transfer. Any sale or
other disposition of any of the Shares by the Optionee, other than according to the terms of this Section 13, shall be void and transfer no right, title or interest in or to any of such Shares to the purported transferee. For purposes of this
Section 13, the term “Shares” shall include all shares of capital stock of the Company held by the Optionee, whether now owned or hereafter acquired. The Optionee agrees to present the certificates representing the Shares hereafter
acquired by him or her to the Secretary of the Company and cause the Secretary to stamp on the certificate in a prominent manner the following legend: 
 “THE SALE OR OTHER DISPOSITION OF ANY OF THE SHARES REPRESENTED BY THIS CERTIFICATE IS RESTRICTED BY A NON-QUALIFIED STOCK OPTION AGREEMENT BETWEEN THE HOLDER OF THIS CERTIFICATE AND THE ISSUER.” 
 If the Optionee desires to sell, transfer or otherwise dispose of any of the Shares, or any interest in such Shares, whether voluntarily or by operation of law, the
Optionee shall first deliver written notice (the “Offer”) to the Company specifying (i) the name and address of the party to which the Optionee proposes to sell or otherwise dispose of the Shares or an interest in the Shares (the
“Offeror”), (ii) the number of Shares the Optionee proposes to sell or otherwise dispose of, (iii) the consideration per Share to be delivered to the Optionee for the proposed sale, transfer, or disposition and (iv) all
other material terms and conditions of the proposed transaction. Upon receipt of the Offer, the Company or its designee shall have an option to purchase any or all of such Shares specified in the Offer, such option to be exercised by giving, within
30 days after receipt of the Offer, a written counter-notice to Optionee. The Company or its designee may accept the Offer, in whole or in part, by delivering, within 30 days after receipt of the Offer a written notice thereof to the Optionee,
specifying the number of Shares desired to be purchased by it. If the Company or its designee so elects to purchase any or all of such Shares in accordance with this Section 13, it shall be obligated to purchase, and the Optionee shall be
obligated to sell to the Company or its designee, as the case may be, such Shares at the price and in accordance with the terms indicated in the Offer within 60 days from the date of receipt by the Company of the Offer. The Optionee may sell any or
all of such Shares which the Company or its designee have not so elected to purchase during the 30 days following the expiration of the Offer Period, provided that such sale is made to the Offeror and only pursuant to the terms set forth in the
Offer and, provided, further, that the purchaser thereof shall have executed a writing satisfactory to the Company, agreeing that such purchase shall be subject to the restrictions on transfer set forth in this Section 13. If, however, any or
all such Shares are not sold by the 
  

 - 4 - 

 Optionee in accordance with the terms set forth in the Offer within such 30 days, the restrictions on transfer set forth
in this Section 13 shall again become applicable to such unsold Shares. The provisions of this Section 13 shall terminate on (i) the effective date of a registration statement filed by the Company under the Securities Act of 1933, as
amended (the “Act”), with respect to an underwritten public offering of the Common Stock or (ii) the closing date of a sale of assets or merger of the Company pursuant to which shareholders of the Company receive securities of a buyer
whose shares are publicly traded. 
 14. Lock-Up Agreement. Upon the request of the Company or the managing underwriter(s), the
Optionee shall, in connection with any public offering of securities of the Company, agree in writing that for a period of 180 days from the effective date of the registration statement for such offering filed with the Securities and Exchange
Commission, plus such additional period, not to exceed 18 days, as may be necessary to enable the underwriter(s) to comply with Conduct Rule 2711(f) of the National Association of Securities Dealers, Inc., the Optionee will not sell, make any short
sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares of the Company’s common stock owned or controlled by him. It shall be a condition to any transfer of the Shares prior to an initial public offering of the
Company’s common stock that the transferee agree to be bound by the foregoing lock-up provision. 
 15. Miscellaneous. In case
any one or more of the provisions or part of any provision contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other
provision or part of this Agreement, but this Agreement shall be construed as if such invalid, illegal or unenforceable provision or part of a provision had never been contained herein. This Agreement shall be binding upon and inure to the benefit
of the parties hereto, and to their respective heirs, executors, administrators, successors and assigns. This Agreement shall be governed by and construed and administered in accordance with the laws of The Commonwealth of Massachusetts 

[the remainder of this page is intentionally blank] 
  

 - 5 - 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the Date of Grant
specified in Schedule A. 
  

			
	 MEMSIC, INC

		
	 By:
	 	  

	 Title:
	 	  

	  
  

	 [Name of Optionee]

  

 - 6 - 

 MEMSIC, INC. 
 NON-QUALIFIED STOCK OPTION AGREEMENT 
 SCHEDULE A 
 This Schedule A sets forth certain information and provisions referred to in the Non-Qualified Stock Option Agreement to which this Schedule A is appended. 

1. The Optionee is [NAME] whose address is
                                        
                    , and whose social security number is
                        . 
 2. The number of option Shares is
                                        .

 3. The option price per Share for such option Shares is
$                            . 
 4. The Date of Grant of the Option is
                                        .

 5. The Expiration Date of the Option is
                                        .

 6. The Option shall become exercisable by the Optionee in 4 equal installments. The Option will become exercisable with respect to 25% of the shares
subject thereto on                      and with respect to an additional 25% of the shares subject thereto on each subsequent anniversary of
such date until the Option is fully exercisable on                     . The foregoing schedule shall accelerate by 12 months upon any of the
following events: (i) a sale of all or substantially all of the Company’s assets, (ii) a sale of all or substantially all of the capital stock of the Company or (iii) the merger or consolidation of the Company in which the
stockholders of the Company immediately prior to the transaction hold securities representing less than 50% of the voting power of the surviving entity immediately after the transaction. The closing of a public offering of shares by the Company
pursuant to an effective registration statement under the Securities Act of 1933, as amended, shall not trigger such one year acceleration. In no event shall any part of the Option be exercisable after the Expiration Date. 
  

 - 7 -Transcript of November 20, 2007 Senetek Shareholder Conference Call

 Exhibit 10.1 
 Senetek PLC 
 Moderator: Frank Massino 
 November 20, 2007 
 12:00 p.m. ET 
 OPERATOR: Good afternoon. My name is Julianne and I will be your conference operator today. At this time, I would like to welcome everyone to the Senetek PLC shareholder
teleconference. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star then the
number one on your telephone keypad. If you would like to withdraw your question, press star then the number two on your telephone keypad. 
 This discussion will contain forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These
risks and uncertainties include failure to get regulatory approval for our product candidates, market acceptance for approved products, management of rapid growth, risks of regulatory review and clinical trials, intellectual property risks, and
the need to acquire additional products. We would like to refer our audience to the documents that Senetek’s files from time to time with the Securities and Exchange Commission.” 
 “I would now like to turn it over to Bill O’Kelly, Chief Financial Officer of Senetek PLC.” 
  

 1 

 “Good morning and thank you for taking the time to participate in Senetek’s shareholder’s teleconference.
This morning’s opening statement will cover the following topics: 
  

	 	•	 	 A review of the third quarter operating results; 

  

	 	•	 	 The Annual General Shareholders meeting; 

  

	 	 •
	 	 An update on InvicorpTM, ReliajectTM and RNA Interference technology; 

  

	 	•	 	 Skincare and dermatological therapeutics, and; 

  

	 	•	 	 Investor Relations and Capital Structure. 

 Finally,
we’ll open the call to a brief question and answer session. 
 Beginning with the financials, our operating results for the third quarter of 2007 were
in line with expectations set when we announced the fully paid license with Valeant earlier this year. 
 Total revenues for the third quarter of 2007 were
$469,000, compared to revenues of $2,027,000 in the third quarter of 2006. Currently, all of our revenues are derived from licensed monoclonal antibodies and this will remain the case until skincare revenues from new compounds are realized. We may
possibly have some initial recognition of revenues related to our collaboration with Triax late in the fourth quarter of 2007 with the full effect beginning in 2008. 
 We reported a net loss of $998,000 for the third quarter and expect to report a net loss in the fourth quarter of this year due principally to initial sales and marketing expenses related to the Triax collaboration
and increased levels of research and development spending. We currently anticipate that we will be profitable in 2008 based on the economics of the Triax agreement. 
  

 2 

 We ended the third quarter of 2007 with $20.6 million in cash. We will use cash in operations for the balance of 2007 but
we anticipate that our cash position will remain very strong during that period, that we will return to cash flow positive operations in 2008 and that we will continue to be financially well positioned to execute on our strategy. 
 I will now turn the call over to Frank for the balance of the opening remarks. 
 Thank you, Bill... 
 Good morning, and thank you for tuning into the Third quarter shareholder teleconference. I would like to first
address the recently adjourned Annual General Meeting and then provide a business update. 
 The 2007 Annual General Meeting was adjourned due to a lack
of a quorum. Although we have a mere 200 ordinary shareholders representing less than .6% of total capital ownership, our bylaws dictate that we must have two ordinary shareholders present at the Annual Meeting. This class of shareholder
did not receive notification of the meeting and proxies due to an error made by our proxy solicitor. This is not in good standing with our contract and therefore, we are confident that all expenses relating to this meeting, to include
travel expenses shall be reimbursed by the proxy solicitor. 
 Although an insignificant number of shares were not voted as a result, management and the
Board felt it imperative that any individual shareholder, regardless of the size of their holdings, should be entitled to vote. We have published a status report on the votes tabulated to date and all resolutions are in good standing to
pass. 
  

 3 

 Now, with regards to our business, I will begin with InvicorpTM. We have two partners, Ardana BioSciences for Europe and Plethora Holdings for North America. First, I report that we have held discussions with the new management at Ardana
BioSciences and were quite pleased with the outcome. We are convinced that Ardana has a commitment to InvicorpTM, nonetheless, they have encountered significant difficulties with the
Danish Medicines Agency, who has been overburdened and understaffed to see many filings through the European Union. Approximately two weeks from today, Senetek and Ardana will reconvene to review Ardana’s strategies for gaining Pan
European approval going forward. We were left with the note that Ardana would be quite aggressive in their actions. 
 On the North American front, Plethora continues to make great progress with the FDA, still projecting InvicorpTM to be launched in the US market in late
2009. Perhaps even more important, several companies have expressed interest in InvicorpTM for the other significant worldwide territories - BRIC - as we collectively call it in the
industry... Brazil, Russia, India and China. Having said that, we have contractual items in our existing InvicorpTM agreements that we must take care of before we finalize any
transaction. 
 I am sure many of you are aware of the recent findings that several Viagra users have
had the unfortunate adverse event of sudden deafness. Couple this with the contraindications of use in cardiovascular impaired patients, issues with vision and ineffectiveness in the moderately severe to severe ED patient, the future indeed
looks bright for InvicorpTM. 
  

 4 

 Transitioning to another ancillary but key technology, RNA Interference, we are pleased to report excellent results in
human clinical trials. A total of 46 patients have been treated with this specific RNAi sequence and results will be announced in the near future. One example of an extraordinary result relates to an individual diagnosed with grade 3
glioblastoma multiforme... average life expectancy from diagnosis equals 8 months... treated and alive 24 months post diagnosis, having returned to work.
 It is important for you the shareholder and/or potential future investor to know, that our RNAi technology is beyond theory, and proof of concept exists., It is a commercially viable asset. Our goal is to partner with a major pharma
company to bring this technology to market. 
 Transitioning to ReliajectTM, a proprietary drug delivery system, we are happy to report progress with this technology. Due to confidentiality, we cannot name specifics but Ranbaxy is working towards a collaboration with another company
for use of the ReliajectTM with their product. This joint effort would in effect help speed up the regulatory approval process for epinephrine in the ReliajectTM. Again, we are expecting revenues from ReliajectTM to hit sometime in late 2009. 
 Moving on to our core competency, skincare and dermatological therapeutics, we are pleased to announce that
product for the initial Triax/Senetek clinical seeding program for Pyratine-6TM has been produced and will be underway by December 1, 2007. The initial launch of the product will
take place at the 2008 American Academy of Dermatology meeting in San Antonio on 
  

 5 

 
February 9th. The Pyratine-6TM clinical trial results for antiaging are currently
being written up and should appear in a Dermatology journal in the first quarter. Triax has hired a highly respected Public Relations firm, the Berman Group to help create media attention and drive patients into the physician’s offices.

 The Pyratine-6TM acne rosacea study
conducted at the Department of Dermatology at the University of California at Irvine has been completed with excellent findings. These findings will be published in the near future once the final patient completes his last treatment visit, thus
allowing final tabulation and statistical analysis of the study results. At the request of the patients and the attending physicians we are extending the study for another 9 months - the patients were insistent on being able to continue
using the product. The initial findings will also be written up and submitted for journal publication. The estimated acne rosacea market worldwide, by year 2008, is projected to be $738 million. 
 As you may or may not know, our pipeline in the skincare and dermatological therapeutic area is rich, with 23 of 47 new compounds being successfully screened for
biological activity and lack of toxicity at the cellular level. A detailed strategy is being put in place with an emphasis on accelerated development of several of these compounds, targeting therapeutic areas with unmet needs. One area that we
are focusing on is wound care, with a projected worldwide market of $15.3 billion by 2010. 

  

 6 

 
On the Investor Relations side, we presented at the 9th Annual Rodman and Renshaw Healthcare Conference. In addition, an independent research report was
filed with the Value Investor’s Club, a private internet site for professional investors. We have been interviewing candidates for the express purpose of handling Senetek’s IR needs. 
 In reference to our capital structure, we can get into more specifics on the timing of the reverse stock split during the Q&A session. You should know that
we have taken the first step in contacting both the NASDAQ small cap and the American Stock Exchange regarding a potential National listing. As we get more definitive answers, we will update our shareholders via a shareholder teleconference
coupled with a press release and 8-K filing if required. 
 Now, I would like to open the floor up for questions and answers, noting that we have limited
time. 
 OPERATOR: Thank you. At this time, I would like to remind everyone, if you would like to ask a question, please press star then the number one on
your telephone keypad. We’ll pause for just a moment to compile the Q&A roster. 
 Your first question is from the line of Jack Scott with Jack
Scott Asset Management. 
 JACK SCOTT, JACK SCOTT ASSET MANAGEMENT: Hey Frank. 
 FRANK MASSINO: Yes. 
  

 7 

 JACK SCOTT: Hey good morning. I wanted to, well first of all, the things that you’ve mentioned are all very good,
very encouraging. The thing that’s concerning me greatly, to be honest, is the fact that while you’re considering bringing on an additional IR, an IR person again, that what really is needed here, in my opinion, is a significant PR firm.
Now you’ve mentioned Berman Group that Triax has hired. The question there is one, how much exposure is that going to be for Senetek because the reality of it is, Frank, despite the, you know, and I would say very good job that you’ve been
doing identifying product and, you know, bringing these products to market. The reality is that the job of a CEO is also to help realize shareholder value. And while we have had an increase in the share price from 19 cents last year to 33, 34, today
and we were as high as 43, the fact of the matter is that currently Senetek’s market cap is about that of its cash value, maybe even less. And the reality of it is, is that given the pipeline that you’ve described and the product and
everything that’s coming down the road, if this company were exposed to a greater audience in terms of PR and getting out and getting the message out to the world beyond just its current investor base, because we all know about it, then in my
opinion this stock would be probably double what it is right now given comparable stocks that are listed at similar prices. 
 So what I’d like to hear
from you, and I’m sure all of the other investors who have been with you for many, many years, as we have, would like to hear is that what is going to be the program, not on the IR front, but on the PR front. What is going to be the plan to get
the Senetek story, which is a great story, told to a new generation of investors? 
  

 8 

 FRANK MASSINO: That’s a very good question Jack, and I would agree with you. First and foremost, what we are doing,
and I was remiss in not stating this in the introduction, we are in the process of shoring up our headcount, making an offer to bring on an Executive Director of Operations. We’re also interviewing additional business development candidates and
a product manager. We believe that we are now situated with the cash and the technology and with the right team we can move these things forward. And you are absolutely correct that my job is to promote the company and not be as much on the
operations side as I have been in the past. 
 The idea behind having an IR person solely dedicated to Senetek, is that this individual would also reach out
to potential new investors and work towards getting media exposure. And I can assure you that we are still in search of a significant PR firm but it has been challenging. 
 We do think there will be some rub off with the Berman Group, and quite candidly in meeting with the Berman Group,
there’s a possibility that they could be a choice for Senetek as well. Keep in mind that the Pyratine-6TM trademark is a Senetek trademark and the packaging will have Senetek on it as
well as Triax. This should provide both corporate and brand recognition 
 JACK SCOTT: The question I have, Frank, that’s great – and you just said
something. You said it’s been challenging getting a PR firm. Can you just, can you explore that a little bit? What’s the, what’s the issue in getting, really, like for example, a Rubenstein or some such firm in New York? What’s
the challenge there because I’ll be honest with you, what I’d love to see here is, look you’re a pretty articulate expert on skin care and skin products, et cetera. And, when one flips through the dial on the TV, you see all kinds of
people talking about skin care and new products and, to me, you ought to be on the TV talking about what Senetek is doing? 
  

 9 

 FRANK MASSINO: We would agree with you. And I have to say that perhaps it’s not been so much enlisting the support
or the attention of an IR/PR firm, a public relations firm, it’s been the execution and the management of it. And quite candidly, Jack, what has happened is that it seems every time we go with some of the companies, we get all these promises,
and they’re not delivered. And it’s always a two-way street, so I’m not going to just push it back to the PR firm. But it’s interesting that, historically we’ve dealt with tremendous turnover in staff at these agencies.
Rubenstein, by the way, is a good company to look into. If there’s anybody in the audience that has ideas or contacts that would give us that attention, we definitely would sit down with them. 
 JACK SCOTT: Well I will be happy to offline because I do have a relationship with Rubenstein and I would be happy, more than happy to arrange for you to chat with the
appropriate people over there. 
 FRANK MASSINO: I would like that. I sincerely would. You know, you are absolutely correct. We’re not going to sit here
and say that your points are not well taken. And I know people say, well, you spend money, you pay $15,000 a month, whatever, for a PR/IR firm. Yes, based on the fact that we might have done it a little prematurely and we probably didn’t do the
screening that we should have in the past, we will now definitely be very focused and hardnosed about who we do bring on. 
  

 10 

 JACK SCOTT: Well that would be, that would be great. Well I wish you a lot of good luck and Happy Thanksgiving.

 FRANK MASSINO: I appreciate that. Same to you. 
 OPERATOR:
Your next question is from the line of Hayes Martin, a private investor. 
 HAYES MARTIN: Well hi Frank. 
 FRANK MASSINO: Good morning Hayes. 
 HAYES MARTIN: Yes, for the benefit of
the audience on the call, I attended the Rodman & Renshaw presentation by Senetek a couple of weeks or so ago and I thought it was excellent. And I was extremely impressed with the slide presentation on the uniqueness of PRK and the HPA,
whatever it’s called, compound, comparing it to Kinetin and essentially blowing away Kinetin on a number of different parameters. So I am more sold than ever that I think you really have some uniqueness here. 
 Frank, could you give a little bit greater insight into the two new compounds, how they differ, not just from Kinetin but from the compounds which are typically out
there today in the most popular products being sold. 
  

 11 

 And where did this uniqueness come from? I was interested when you showed that you could decrease course wrinkles, which
you mentioned is a very unique thing in addition to fine wrinkles. Is that an effect of stimulating collagen production? I know also that the anti-inflammatory properties, I think, are quite unique here, could you explain some of that to us
comparative to other technologies currently available? 
 FRANK MASSINO: Yes, Hayes. I will start with
the PRK124, the Pyratine-6TM that Triax will be launching. It does have different attributes than the 4 hydroxy BAP, which is the second compound. They definitely are differing with regards
to their activity. Now they are both cytokinins just like Kinetin is a cytokinin, but they’re a different classification of cytokinins. They’re new. And I will tell you that for the mechanism and mode of action, we understand some of it,
but we are doing additional detailed studies with regards to its actual pinpointed mechanisms of action. And some of our partners are working on this as well. But if we were to take a look at Pyratine-6TM and you would compare it to, say, Kinetin or TNS recovery factor by Skin Medica or Allergan’s PrevageTM, I think you’ll find that Pyratine-6TM will be faster acting, and that’s probably one of the most important things when you start speaking to a person that has photo damaged skin or aging skin. They want results immediately.

 Another attribute I think that really stands out with Pyratine-6TM, is it’s ability to reduce erythema, redness. I made a comment in my presentation on the acne rosacea patient. The acne rosacea patient actually has a lot of redness, and the fact is that if you can imagine,
every patient really pressed upon the clinicians to continue with the treatment, and we actually had 20 of 24 patients sign up for additional trials, a 9 month extension. This demonstrates we have a product that is really proven to reduce the
redness. That is one of the most significant attributes I think that Pyratine-6TM does offer. The effect on erythema, that is the improvement in skin color, will be superior to the products
currently in the market. 
  

 12 

 In addition, I will tell you that our formulations are aesthetically appealing to the consumer. 
 The 4 hydroxy BAP is, in my opinion, and from the data, is a little more heavy duty in some cases than
Pyratine-6TM which also treated course wrinkles. Now I want to make a note that there’s nine parameters that the FDA will look at for a product to be approved for anti-aging, and
course wrinkles is one of them. It’s the most difficult parameter to treat. Pyratine-6TM really outperformed the results you would see with RenovaTM, the only approved prescription product, and you saw the results against Kinetin. But the amazing thing is the phenomenal result that we saw with 4 hydroxy BAP. It was just incredible, the statistically significant
improvement that we saw in the treatment of course wrinkles. So we definitely think that 4 hydroxy BAP will be and can be positioned differently. 
 In
addition, we found in the clinical trials that 4 hydroxy BAP had activity against acne vulgaris, not to be confused with the acne rosacea, which is the redness. People sometimes confuse it with the different indications. They don’t even know
what acne rosacea is. The acne vulgaris, I think we all know, is inflammatory pustules and pimples. With 4 hydroxy BAP, we have a compound we think should be studied further for acne vulgaris. 
  

 13 

 Both compounds have anti-inflammatory activities and reduce the epidermal cell turnover. We have not pinpointed the exact
mechanism but we certainly have really great clinical data that these are very, very therapeutic products. 
 HAYES MARTIN: Frank, just one other thing, with
these unique properties and the Triax deal I gather is North, is U.S. ethical, obviously there’s a vast global market potentially for products with these kind of features. Are you currently in negotiation with some heavy hitters to make deals
to tackle Europe, the Far East, South America, other major markets? 
 FRANK MASSINO: Unequivocally yes, Hayes. And I will tell you that, for example, I keep
emphasizing the reduction of redness, erythema. This translates into being an excellent potential skin whitener, skin lightener compound. In Japan alone, as far back as 2001, the market there was $500 million. And it’s been growing at a
double-digit compound annual growth rate. And so it’s over a billion. One of our partners is looking at filing for quasi medicated drug status in Japan. So yes, we are working with a lot of different partners that traverse the universe.

 Now I’ve always been accused as far as being a little bit enthusiastic and saying it’s going to happen tomorrow. What I do say, and I think that
most people will agree that it does happen with time... well, most of these are large players, and thus it does take a longer time. We’re not looking for a quantity of partners. We’re looking for quality of partners. So you have to bear
with us. 
  

 14 

 HAYES MARTIN: Frank, just one last thing. I was interested in Jack’s point about your being an expert. And hearing
you talk now, you have a remarkable perspective and knowledge of the various skin care technologies available, and I would agree completely with Jack that I think as part of Senetek’s PR program in the future that you should be positioned
through PR people to be an expert who would be on television and comment in the media. And I think this could be extremely beneficial to enhancing Senetek’s overall public image. 
 FRANK MASSINO: I appreciate that Hayes, and I think that is the goal of the board as well as management. The fact is, we all know that I’ve run a very lean ship here, and we are very excited about some of the
people that we have identified, and we do have an offer letter going out to an individual that we think can really help take Senetek to the next level and free me up to do more public speaking. 
 HAYES MARTIN: Great. Look forward to that Frank. 
 FRANK MASSINO: Thank you
Hayes. 
 OPERATOR: Your next question is from the line of Tom Seymour, a private investor. 
 TOM SEYMOUR: Good morning Frank. Congratulations again to you and the Senetek team, good job. 
  

 15 

 FRANK MASSINO: I appreciate that. We’re still not there Tom at the share price, and that’s not...

 TOM SEYMOUR: I know I’m looking for that too, but one of the things that you’ve mentioned in the past, I didn’t even hear the words merger
acquisition this morning, I’m looking at the things we’re going to be voted on or were voting on, and there were a couple that kind of suggest maybe something in the wings or just to be prepared. Anything in the wind for merger
acquisition, any of that stuff that you can talk about. 
 FRANK MASSINO: I’ll give you some factual feedback. With regards to merger and acquisitions,
we have a couple of companies that have approached us, but it’s our belief right now that we’re totally undervalued and if we were to do a merger, we would be trading or dealing in currency or stock that’s undervalued. It’d be
like dealing with the dollar against the UK pound. I don’t really think that it’s appropriate at this time. Bill and I have been working on an acquisition for a small unnamed company that had about five million dollars in revenue, but as
we went into the due diligence, quite candidly, it did not really pan out. We are looking at potential mergers and acquisitions but what we have to always keep in mind is that we must always stay focused. , Do chicken and do chicken right, like that
commercial used to say. 
 TOM SEYMOUR: OK. One related question then I’ll let others in, along with that, on the capital structure, you touched on that
a little and it looks like we’re going ahead with a reverse split to your next month. You mentioned about talking to AMEX and NASDAQ but could you expand anymore on where we’re at on that and I’m particularly interested and asked you
before about migrating to America and being in a position to buy back stock because, there again, I think we’re selling so cheap I wish we were able to take some off the table. Could you kind of address that a little bit? 
  

 16 

 FRANK MASSINO: Yes, I’ll start briefly and then turn it over to Bill, particularly on the timelines for the reverse
stock split and the mechanics. We would agree with you that it would be a great time to buy back our stock but because of our accumulative deficit account we can’t at this time, being a U.K. company. The fact is, is that the migration to the
U.S., that’s an alternative but I will tell you that we’re talking a seven figure transaction cost as far as doing that plus about 40 million NOLs lost in Europe. I remember a point a shareholder made that you can’t use the ADR
as an excuse for the stock price not being up there because Glaxo SmithKline was an ADR. I believe Toyota is an ADR and many of these companies have done well. I’ll never say never, but I’m not so sure it’s the wisest use of our money
right now. Bill will speak to this a little bit more in detail. 
 BILL O’KELLY: Yes, on the migration issue, there is, there are a lot of troublesome
issues with regards to both the expense of actually doing that type of a transaction and the loss that we would incur because of our net operating losses and the fact that it would probably be a taxable transaction in the U.K. We’ve studied
this to great length over the past year. We’ve tried to figure out different alternatives to it, but it always comes up at a pretty substantial cost and that’s the situation we’re in with regards to that. In terms of the reverse stock
split, we will give notice to the exchange on the 30th of November and the split will be affected around the 14th of December. It’ll be approved and finalized on the 10th and affected on or around the 14th. That’s the timeline that the
Bank of New York, our agents, have given us at this point in time. 
  

 17 

 FRANK MASSINO: We also have Chip Nichols on the line. As you know, Chip is an attorney that has been in-house with us and
currently works in a consulting capacity. Chip has also been deeply involved in the evaluation of migrating to the U.S. Chip, is there anything that you would like to say about the buy back of shares and a migration to the U.S. from a legal
perspective? 
 CHIP NICHOLS: Well, I think you both covered all of my thoughts on it, except to concur with you, Frank, that there’s nothing awful
about being an ADR security and, in fact, in terms of flexibility of the original listing and maintenance of listing with both of the organizations you mentioned, NASDAQ and AMEX, in fact, foreign assures have a somewhat easier go, so...

 FRANK MASSINO: I appreciate that Chip. 
 TOM SEYMOUR: Thanks
Frank. You guys have answered my questions and keep doing what you’re doing. 
 FRANK MASSINO: Thank you Tom. 
 OPERATOR: Once again, in order to ask a question, please press star, one. Your next question is from the line of Richard Sandefur, a private investor. 
  

 18 

 RICHARD SANDEFUR: Good morning. 
 FRANK MASSINO: Good morning Richard. 
 RICHARD SANDEFUR: My question has to do with our partnership with Triax in 2008. How would you characterize
it? I’m a little bit confused; a littler murky on the launch that we have for our product with them. Is that going to be a great big launch initially and then carrying through that or is it going to be a more gradual type of launch? You said a
few things about that but could you say a little bit more? 
 FRANK MASSINO: Right. As I mentioned, we
have produced actual product and we are looking at a clinical seeding program with noted dermatologists to begin in December of this year. They will try the product and provide us feedback on the product’s attributes, phase IV marking, as you
might call it. The actual launch will be at the American Academy of Dermatology which starts around February 9th in San Antonio, Texas and that will be a major campaign and the fact of the matter is, I can’t disclose specifically all the
plans that Triax has, but you should know that they’ve signed a seven figure contract with the Berman Group to rapidly accelerate the awareness of Pyratine-6TM. They’re extremely
excited about this product and I will tell you I feel very confident and comfortable with Pyratine-6TM being in the hands of Triax. You’ll see a lot of noise level. 
  

 19 

 RICHARD SANDEFUR: What could you say about the revenue to us with that program, with that marketing program? Will our
revenues sort of be backend loaded or will we see some substantial revenue sort of at the frontend as well? 
 FRANK MASSINO: I think that you’ll see
revenues in the beginning. I think that you’ll see more of an accelerated climb towards the end but that $10.8 million guarantee, well, we expect for them to blow by that, to actually do better than $10.8 million in revenues but yes,
you’ll see revenues along the way. They will be booked as they come in and I think that early on you’ll see a bolus of revenues. You might see a little flattening period and then followed by increases. 
 RICHARD SANDEFUR: OK. Then a final question; on the meeting that’s planned for December, do you think that you’ll be able to have a quorum there and get that
disposed of, the meeting disposed of at that point? 
 FRANK MASSINO: Yes, absolutely. Just so you know that at the last meeting, I was the only ordinary
shareholder in attendance but since then Bill has become an ordinary shareholder and that will take effect by the date of the reconvened meeting. We will definitely have a quorum for the meeting. 
 RICHARD SANDEFUR: OK thanks. 
 FRANK MASSINO: Sure. 
  

 20 

 RICHARD SANDEFUR: Keep up the good work. 
 FRANK MASSINO: Thank you. 
 OPERATOR: Your next question is from the line of Charles Kusnyer, a private investor.

 CHARLES KUSNYER: Hey good afternoon. On the RNA Interference, could you give us a little bit more information regarding your, the partnership that
you’re seeking and also like what the costs will be as to get that product out in the marketplace? 
 FRANK MASSINO: Yes. Charles, just so you know,
there’s a lot of companies out there with RNA Interference technology and other variations of that technology. We are somewhat fortunate that we are actually in clinical trials and have good results so we have proof of concept, and that’s
all being done in Poland and the fact is that all 46 patients are still alive. The key is that we’re looking for a major pharma company to partner with. The idea of the deal structure would be a large upfront payment and royalty on net sales.
We don’t expect to use our money to take it any further into development because that’s not our focus. We’re a life science company with a focus on the study of senescence, aging, with an emphasis in the area of skincare and
dermatological therapeutics, but this has the potential of being a blockbuster and the great thing about it is that it should have fast track through the FDA during the filing, so many companies will have an interest in this compound. 
 CHARLES KUSNYER: Thank you Frank. 
  

 21 

 FRANK MASSINO: Sure. 
 OPERATOR: There are no further questions at this time. I would now like to turn the call back over to Mr. Massino for any closing remarks. 
 FRANK MASSINO: Thank you everyone for participating and have a Happy Thanksgiving. Bye now. 
 END 
  

 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]